A new cancer drug candidate developed by Lawrence Livermore National Lab, BridgeBio Oncology Therapeutics and the Frederick National Laboratory for Cancer Research shows the ability to block tumor growth without a common side effect ….
Livermore Lab: Cancer Drug Candidate Developed Using HPC and AI Blocks Tumor Growth
June 27, 2025 by
Livermore Lab and BridgeBio Announce Human Trials for HPC-Discovered Cancer Drug
June 6, 2024 by
In what Lawrence Livermore National Lab said is “a substantial milestone for supercomputing-aided drug design,” LLNL and BridgeBio Oncology Therapeutics today announced clinical trials have begun for ….
